CD274 and lung cancer: Indeed, a randomized phase 2 trial of combination therapy with anti-PD-L1 mAb and anti-TIGIT mAb has demonstrated favorable efficacy against PD-L1 high lung cancer, which can reflect inflamed TME,50 and a phase 3 trial is currently ongoing (NCT04294810).